Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DIPGen: Molecularly Guided Targeted Therapy in Pediatric DIPG
2024-515952-19-00Phase 2Authorised
- Sponsor
- Children's Memorial Health Institute
- Start
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of sirolimus and trametinib in diffuse intrinsic pontine glioma (DIPG) (2 arms), sponsored by Children's Memorial Health Institute. Primary endpoints: Overall survival and Safety of sirolimus and sirolimus + trametinib. Planned start Dec 2024; status: authorised.
02
Drugs
sirolimustrametinib
03
Conditions
diffuse intrinsic pontine glioma (DIPG)
Beyond the preview
Go deeper on 2024-515952-19-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515952-19-00.